Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068801637> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2068801637 endingPage "S175" @default.
- W2068801637 startingPage "S175" @default.
- W2068801637 abstract "778 The aim of the study was to quantify the effects of moderate supraphysiological doses of recombinant human erythropoietin (rhEPO) on maximal O2 uptake and soluble transferrin receptor (sTfr) concentration. METHODS: Twenty healthy, endurance trained male athletes, age: 24±3 yrs, weight: 75±5 kg, max. O2 uptake: 61.4±4.5 ml kg−1 min−1 (±SD) were matched for sport and training level and randomly assigned to the EPO group (n=10; 5000 IE Recormon (Boehringer Mannheim GmbH) s.c. three times weekly for 30 days or until hematocrit (Hct) reached 50) or the placebo group (n=10; NaCl s.c.). The groups were followed for 4 wks post-administration with regular blood samples and exercise tests. Subjects and laboratory personnel were blinded to the group assignments. Max. O2 uptake was measured in an exercise test on a cycle ergometer (starting load: 100 W, increased by 50 W every 2. min) at the start of the study, 2, 7, 14, 21 and 28 days post rhEPO administration. RESULTS: There was an increase in Hct from 42.7±1.6 before to a maximum value of 50.8±2.0 the day after the end of the rhEPO administration period in the EPO group. Maximal O2 uptake increased from 63.6±4.5 ml kg−1 min−1 (before) to 68.1±5.4 ml kg−1 min−1 (2 days post rhEPO administration; 7% increase, p=0.002 vs before), 67.6±5.2 ml kg−1 min−1 (after 1 wk; p=0.008 vs before), 67.1±6.5 ml kg−1 min−1 (2 wks; p=0.28 vs before), 66.6±4.4 ml kg−1 min−1 (3 wks; p=0.011 vs before), and 65.8±4.7 ml kg−1 min−1 (4 wks; p=0.14 vs before) in the EPO group. The concentration of sTfr increased in the EPO group from 3.1±0.9 mg l−1 (before) to a maximum value of 6.3±2.3 mg l−1 2 days post rhEPO administration. The sTfr increase was significant after one week of rhEPO administration and remained increased for one week post rhEPO administration. The sTfr concentration was higher than the average basal value plus 2 SD after 30 days of rhEPO treatment in 8 out of 10 subjects in the EPO group. There were no significant changes in Hct, maximal O2 uptake or sTfr concentration in the placebo group. CONCLUSION: Serum sTfr concentration may represent a potential screening method for rhEPO doping, but since the effect on performance outlasts the increase in sTfr, pre-competition lesting is necessary." @default.
- W2068801637 created "2016-06-24" @default.
- W2068801637 creator A5000563662 @default.
- W2068801637 creator A5007196302 @default.
- W2068801637 creator A5011164322 @default.
- W2068801637 creator A5027375616 @default.
- W2068801637 creator A5046741894 @default.
- W2068801637 creator A5057009985 @default.
- W2068801637 date "1999-05-01" @default.
- W2068801637 modified "2023-10-17" @default.
- W2068801637 title "TIME COURSE OF MAXIMAL O2 UPTAKE AND TRANSFERRIN RECEPTOR CONSENTRATION AFTER rhEPO ADMINISTRATION" @default.
- W2068801637 doi "https://doi.org/10.1097/00005768-199905001-00777" @default.
- W2068801637 hasPublicationYear "1999" @default.
- W2068801637 type Work @default.
- W2068801637 sameAs 2068801637 @default.
- W2068801637 citedByCount "0" @default.
- W2068801637 crossrefType "journal-article" @default.
- W2068801637 hasAuthorship W2068801637A5000563662 @default.
- W2068801637 hasAuthorship W2068801637A5007196302 @default.
- W2068801637 hasAuthorship W2068801637A5011164322 @default.
- W2068801637 hasAuthorship W2068801637A5027375616 @default.
- W2068801637 hasAuthorship W2068801637A5046741894 @default.
- W2068801637 hasAuthorship W2068801637A5057009985 @default.
- W2068801637 hasConcept C126322002 @default.
- W2068801637 hasConcept C134018914 @default.
- W2068801637 hasConcept C140793950 @default.
- W2068801637 hasConcept C142724271 @default.
- W2068801637 hasConcept C196310339 @default.
- W2068801637 hasConcept C204787440 @default.
- W2068801637 hasConcept C22814914 @default.
- W2068801637 hasConcept C27081682 @default.
- W2068801637 hasConcept C2776485076 @default.
- W2068801637 hasConcept C2777417653 @default.
- W2068801637 hasConcept C2777953023 @default.
- W2068801637 hasConcept C2778248108 @default.
- W2068801637 hasConcept C2778534260 @default.
- W2068801637 hasConcept C2778917026 @default.
- W2068801637 hasConcept C2780959883 @default.
- W2068801637 hasConcept C2994262451 @default.
- W2068801637 hasConcept C3019673199 @default.
- W2068801637 hasConcept C32264632 @default.
- W2068801637 hasConcept C71924100 @default.
- W2068801637 hasConcept C84393581 @default.
- W2068801637 hasConcept C86803240 @default.
- W2068801637 hasConceptScore W2068801637C126322002 @default.
- W2068801637 hasConceptScore W2068801637C134018914 @default.
- W2068801637 hasConceptScore W2068801637C140793950 @default.
- W2068801637 hasConceptScore W2068801637C142724271 @default.
- W2068801637 hasConceptScore W2068801637C196310339 @default.
- W2068801637 hasConceptScore W2068801637C204787440 @default.
- W2068801637 hasConceptScore W2068801637C22814914 @default.
- W2068801637 hasConceptScore W2068801637C27081682 @default.
- W2068801637 hasConceptScore W2068801637C2776485076 @default.
- W2068801637 hasConceptScore W2068801637C2777417653 @default.
- W2068801637 hasConceptScore W2068801637C2777953023 @default.
- W2068801637 hasConceptScore W2068801637C2778248108 @default.
- W2068801637 hasConceptScore W2068801637C2778534260 @default.
- W2068801637 hasConceptScore W2068801637C2778917026 @default.
- W2068801637 hasConceptScore W2068801637C2780959883 @default.
- W2068801637 hasConceptScore W2068801637C2994262451 @default.
- W2068801637 hasConceptScore W2068801637C3019673199 @default.
- W2068801637 hasConceptScore W2068801637C32264632 @default.
- W2068801637 hasConceptScore W2068801637C71924100 @default.
- W2068801637 hasConceptScore W2068801637C84393581 @default.
- W2068801637 hasConceptScore W2068801637C86803240 @default.
- W2068801637 hasIssue "Supplement" @default.
- W2068801637 hasLocation W20688016371 @default.
- W2068801637 hasOpenAccess W2068801637 @default.
- W2068801637 hasPrimaryLocation W20688016371 @default.
- W2068801637 hasRelatedWork W1535968422 @default.
- W2068801637 hasRelatedWork W1985083100 @default.
- W2068801637 hasRelatedWork W2018316522 @default.
- W2068801637 hasRelatedWork W2019402054 @default.
- W2068801637 hasRelatedWork W2023286210 @default.
- W2068801637 hasRelatedWork W2031002198 @default.
- W2068801637 hasRelatedWork W2034565548 @default.
- W2068801637 hasRelatedWork W2373176534 @default.
- W2068801637 hasRelatedWork W2418153023 @default.
- W2068801637 hasRelatedWork W4240369490 @default.
- W2068801637 hasVolume "31" @default.
- W2068801637 isParatext "false" @default.
- W2068801637 isRetracted "false" @default.
- W2068801637 magId "2068801637" @default.
- W2068801637 workType "article" @default.